New drug trial aims to help patients walk farther with rare heart condition
NCT ID NCT04622046
Summary
This study tested an experimental drug called ALXN2060 in 25 Japanese patients with a rare heart condition called transthyretin amyloid cardiomyopathy. The goal was to see if the drug could help patients walk farther during a 6-minute test and reduce heart-related hospital visits over 30 months. Participants took the drug daily while continuing their standard heart failure medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Bunkyō City, 113-8431, Japan
-
Research Site
Fukuoka, 812-8582, Japan
-
Research Site
Kumamoto, 860-8556, Japan
-
Research Site
Kurume-shi, 830-0011, Japan
-
Research Site
Matsumoto-shi, 390-8621, Japan
-
Research Site
Nagoya, 466-8560, Japan
-
Research Site
Nankoku-shi, 783-8505, Japan
-
Research Site
Sagamihara-shi, 252-0375, Japan
-
Research Site
Sapporo, 060-8543, Japan
-
Research Site
Shinjuku-ku, 160-8582, Japan
-
Research Site
Suita-shi, 564-8565, Japan
Conditions
Explore the condition pages connected to this study.